作为最早被应用于临床的成体干细胞，造血干细胞（HSC）功能和分化模式一直以来是研究的热点。我们实验室的研究目标是明确HSC在稳态和疾病状态下的内外调控机制，揭示微环境在其中的变化规律继而对HSC的影响机理，探讨HSC选择性保护的分子机制，以期为白血病的治疗提供新的思路和策略。

2012 中国医学科学院&北京协和医学院内科学博士

2007 浙江大学生物信息学学士

2020-至今   协和准长聘助理教授（正高）

2015-2020  中国医学科学院血液病医院（中国医学科学院血液学研究所）副研究员

2016-2017  以色列魏茨曼科学院访问学者

2013-2015  中国医学科学院血液病医院（中国医学科学院血液学研究所）科研助理

1.    国家重点研发计划，2020YFE0203000，克隆性造血相关疾病的防控与机制研究，2020.11-2023.08

2.    国家自然科学基金优秀青年科学基金项目，81922002，造血干细胞的生理与病理调控机制，2020.01-2022.12

3.    国家自然科学基金面上项目，81870086，单细胞尺度解析白血病下造血干/祖细胞及其微环境的变化规律及机制，2019.01-2022.12

4.    国家自然科学基金青年科学基金项目，81400077，Egr3调控造血干细胞功能的机制研究，2015.01-2017.12

5.    2019年天津市杰出青年科学基金

6.    2018年首批天津市“青年医学新锐”

7.    2018年第三批天津市“青年拔尖人才支持计划”

8.    中国医学科学院医学与健康科技创新工程，细胞异质性的表观遗传调控机理，2017.01-2020.12，子课题负责人

(1) Wang FJ. #, He J.#, Liu S.#, Gao A., Yang L., Sun G., Ding W., Li C., Wang F., Wang X., Zhu P., Hao S., Ma Y.*, Cheng H.*, Yu J.*, Cheng T*. Comprehensive RNA Editome Reveals Edited Azin1 as A DDX1 Partner to Facilitate Hematopoietic Stem Cell Differentiation. Blood (in revision).

(2) Huang D.#, Sun G.#, Hao X.#, He X.#, Zheng Z., Chen C., Yu Z., Xie L., Ma S., Liu L., Zhou B., Cheng H.*, Zheng J.*, and Cheng T*. ANGPTL2-containing small extracellular vesicles from vascular endothelial cells accelerate leukemia progression. J Clin Invest. 2021;131(1).

(3) Wang T.#, Xia C.#, Weng Q., Wang K., Dong Y., Hao S., Dong F., Liu X., Liu L., Geng Y., Guan Y., Du J., Cheng T., Cheng H.*, Wang J*. Loss of Nupr1 promotes engraftment by tuning the quiescence threshold of hematopoietic stem cell repository via regulating p53-checkpoint pathway. Haematologica. 2020.

(4) Zhang C.#, Xu Z.#, Yang S.#, Sun G.#, Jia L., Zheng Z., Gu Q., Wei Tao W.*, Cheng T.*, Li C.* and Cheng H.*. tagHi-C reveals 3D chromatin architecture dynamics during hematopoiesis. Cell Reports. 2020;32(13)

(5) Dong F., Cheng H.*, Ema H.*, Cheng T*. Probing the fate of transplanted hematopoietic stem cells: is the combinational approach "FIT" for purpose? Sci China Life Sci. 2020;63(11):1755-8.

(6) Dong F.#, Hao S.#, Zhang S.#, Zhu C.#, Cheng H.#, et al. Differentiation of transplanted haematopoietic stem cells tracked by single-cell transcriptomic analysis. Nature Cell Biology. 2020;22(6):630-9.

(7) Xia C.#, Wang T.#, Cheng H.#, et al. Mesenchymal stem cells suppress leukemia via macrophage-mediated functional restoration of bone marrow microenvironment. Leukemia. 2020;34(9):2375-83.

(8) Ma S.#, Sun G.#, Yang S., Ju Z.*, Cheng T.*, Cheng H.*. Effects of telomere length on leukemogenesis. Sci China Life Sci. 2020;63(2):308-11

(9) Wang Y.#, Lu T.#, Sun G.#, Zheng Y.#, Yang S., Zhang H., Hao S., Liu Y., Ma S., Zhang H., Ru Y., Gao S., Yen K.*, Cheng H.*, Cheng T.*. Targeting of apoptosis gene loci by reprogramming factors leads to selective eradication of leukemia cells. Nature communications. 2019;10(1):5594.

(10) Gao A.#, Gong Y.#, Zhu C., Yang W., Li Q., Zhao M., Ma S., Li J., Hao S.*, Cheng H.*, Cheng T*. Bone marrow endothelial cell-derived interleukin-4 contributes to thrombocytopenia in acute myeloid leukemia. Haematologica. 2019;104(10):1950-61.

(11) Cheng H.#*, Zheng Z.#, Cheng T.*. New paradigms on hematopoietic stem cell differentiation. Protein & Cell. 2019;11(1):34-44.

(12) Cheng H.#*, Sun G.#, Cheng T*. Hematopoiesis and microenvironment in hematological malignancies. Cell Regen (Lond) 2018;7:22-26

(13) Gong, Y., Zhao, M., Yang, W., Gao, A., Yin, X., Hu, L., Wang, X., Xu, J., Hao, S., Cheng, T*. and Cheng, H*. Megakaryocyte-derived excessive TGFbeta1 inhibits proliferation of normal hematopoietic stem cells in acute myeloid leukemia. Exp Hematol. 2018;60:40-46

(14) Cheng H., Liu Y., Jia Q., Ma S., Yuan W., Jia H., and Cheng T*. Novel regulators in hematopoietic stem cells can be revealed by a functional approach under leukemic condition. Leukemia. 2016;30:2074-77.

(15) Cheng H., and Cheng T*. 'Waterloo': when normal blood cells meet leukemia. Cur Opin Hematol. 2016;23:304-10.

(16) Cheng H.#, Hao S#., Liu Y., Pang Y., Ma S., Dong F., Xu J., Zheng G., Li S., Yuan W., and Cheng T*. Leukemic marrow infiltration reveals a novel role for Egr3 as a potent inhibitor of normal hematopoietic stem cell proliferation. Blood. 2015;126:1302-13.

(17) Liu Y#., Cheng H.#, Gao S., Lu X., He F., Hu L., Hou D., Zou Z., Li Y., Zhang H., Xu J., Kang L., Wang Q., Yuan W., and Cheng T*. Reprogramming of MLL-AF9 leukemia cells into pluripotent stem cells. Leukemia. 2014;28:1071-80.